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Abstract
Cancer has been a major public health problem that has threatened human life worldwide throughout history. The
main causes that contribute to the poor prognosis of cancer are metastasis and recurrence. Cancer stem cells are a
group of tumor cells that possess self-renewal and differentiation ability, which is a vital cause of cancer metastasis
and recurrence. Long non-coding RNAs refer to a class of RNAs that are longer than 200 nt and have no potential
to code proteins, some of which can be specifically expressed in different tissues and different tumors. Long non-
coding RNAs have great biological significance in the occurrence and progression of cancers. However, how long
non-coding RNAs interact with cancer stem cells and then affect cancer metastasis and recurrence is not yet clear.
Therefore, this review aims to summarize recent studies that focus on how long non-coding RNAs impact tumor
occurrence and progression by affecting cancer stem cell self-renewal and differentiation in liver cancer, prostate
cancer, breast cancer, and glioma.
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Background
According to the result of Human Genome Project, only
approximately 20 thousand genes of human genome
have the encoding protein ability [1]. At the same time,
only 5–7% of human genes can be stably transcribed.
The vast majority of RNAs are therefore unable to be
translated into protein and are termed non-coding RNAs
[2–4]. Non-coding RNAs used to be considered by sci-
entists to be “junk RNAs”; however, an increasing body
of evidence suggests that non-coding RNAs play an
important role in both physiological and pathological
conditions [5–7].
Long non-coding RNAs (LncRNAs) are a class of non-
coding RNAs that have no potential to code proteins
and are more than 200 nucleotides in length. Portions of
LncRNAs can be specifically expressed in different tis-
sues and different cancers [8–10]. According to the lit-
erature, the disorder of LncRNAs is closely related to
the occurrence and development of various cancers,
such as leukemia, breast cancer, gastric cancer, colon
cancer, liver cancer, lung cancer, and cholangiocarci-
noma [11–17]. The GENCODE consortium (version 18)
has confirmed the existence of 13,562 LncRNAs, and ap-
proximately 2/3 of them are located between genes,
which are termed long intergenic ncRNAs (lincRNAs).
Others include overlapping, antisense, and intronic
LncRNAs [18]. Most LncRNAs are transcribed by RNA
polymerase II to be spliced, polyadenylated, and 5′-
capped [19, 20]. LncRNAs work mainly in four modes:
signal, decoy, guide, and scaffold [21, 22]. They affect
the transcription of genes and play a regulating role
(Fig. 1) [22]. Signal: LncRNAs can signal the space, time,
and expression of gene transcription to reflect the inte-
grative biological outcome of transcription factors and
signaling pathways controlling gene expression. Decoy:
LncRNAs can bind and titrate away the protein or RNA
target. Guide: LncRNAs can guide RNA-binding pro-
teins to special target genes, either in the near or in the
distant target genes. Scaffold: LncRNAs can assemble
different proteins to form complexes to initiate the spe-
cial biological functions [21, 22]. Compared with coding
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genes and other non-coding RNAs such as microRNAs
(miRNAs), LncRNAs are highly conserved [23]. Their
high conservation and versatility have made them im-
portant in cancer research in recent years.
The tumor complex contains heterogeneous cells of
different differentiation degrees [24]. Cancer stem cells
(CSCs) are a group of tumor cells that have differenti-
ation and self-renewal ability [25]. In 2003, Visvader and
Linderman first defined CSCs in acute myeloid leukemia
[26]. Recently, more research has shown that CSCs are
involved in the occurrence, development, invasion, me-
tastasis, and drug resistance of numerous solid tumors
[27–30], which is closely related to poor tumor progno-
sis. Removal of CSCs is considered a new hope for the
eradication of malignant tumors and the prevention of
tumor recurrence [31].
Some research has demonstrated that the aberrant ex-
pression of LncRNAs in malignant tumors is closely re-
lated to the function of CSCs. Numerous LncRNAs
modulate the functions of CSCs by regulating OCT4,
SOX2, KLF4, and other classic stem cell-related path-
ways [32–34]. In addition, other LncRNAs contribute to
CSC functions and tumor occurrence and development
by inhibiting the miR-200 family, let-7, miR-140, and
other miRNAs [35–37]. In recent years, research regard-
ing LncRNAs and CSCs gradually became important to
cancer researchers. This review aims to summarize the
current research status of LncRNA and CSCs in differ-
ent tumors and to explore the significance of LncRNA
in the removal of CSCs and tumor therapy.
Hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is a global health prob-
lem and is ranked sixth worldwide for malignant tumors
[38]. Over 700,000 patients are newly diagnosed with
HCC every year [39]. Thus, the mechanisms of HCC
development and progression and therapeutic targets
and methods have been the focus of scientists. Increas-
ingly, research suggests that LncRNAs participate in the
self-renewal and proliferation of HCC stem cells by dif-
ferent mechanisms and play important roles in HCC
deterioration.
According to previous research, the high trimethyla-
tion level of histone H3K4 and H3K27 was linked to low
differentiation, a large volume of neoplastic foci, mul-
tiple tumors, vascular invasion, and poor prognosis of
HCC [40, 41]. Li et al. found that LncRNA CUDR could
enhance the interaction between SET1A and phosphory-
lated RB1 (pRB1) in HCC, and the complex they formed
resulted in a high level of H3K4 trimethylation, which
participated in the malignant transformation of HCC
stem cells via altering telomere length [42]. At the same
time, other research suggests that LncRNA CUDR can
also function as an oncogene by the CUDR-HULC/
CUDR-β-catenin signaling pathway [43]. Furthermore,
CUDR inhibits the methylation of the gene promoter
LncRNA H19 by combining with Cyclin-D to form the
complex CUDR-CyclinD1, which upregulates the expres-
sion of LncRNA H19 and finally upregulates the expres-
sion of TERT and C-Myc to promote the self-renewal and
proliferation of HCC stem cells [44] (Fig. 2 (Part 1)). Thus,
it can be seen that LncRNA CUDR plays an important
role in the self-renewal and proliferation of HCC stem
cells by multiple signaling pathways.
In addition, Li et al. reported that LncRNA HOTAIR
can inhibit the trimethylation level of its downstream
histone H3K36 by suppressing the expression of SETD2,
which can enhance the malignant proliferation of HCC
stem cells and accelerate the progression of HCC by af-
fecting the repair of aged histones, microsatellite stabil-
ity, and cell cycle-related genes [45] (Fig. 2 (Part 2)).
Thus, it can be seen that LncRNA can enhance the
Fig. 1 Four models of LncRNAs. Signal: LncRNAs can signal the space, time, and expression of gene transcription to modulate transcription factors and
signaling pathways. LncRNAs directly bind to nucleic acid to inhibit the downstream molecule transcription named signal work model. Decoy: LncRNAs
can bind and titrate away the protein or RNA target. LncRNAs combine with protein and then bind to nucleic acid to inhibit the downstream molecule
transcription named decoy work model. Guide: LncRNAs can guide RNA-binding proteins to special target genes. Proteins guide LncRNA to bind
to nucleic acid to inhibit the downstream molecule transcription named guide work model. Scaffold: LncRNAs can assemble different proteins
to form complexes to initiate the special biological functions. Different proteins and LncRNAs combine together to bind to nucleic acid to inhibit the
downstream molecule transcription named scaffold work model
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malignant transformation of HCC stem cells by regulat-
ing the abnormal modification of histones. At the same
time, scientists have reported that LncRNAs can acceler-
ate the development and progression of HCC by altering
the classic signaling pathways that are related to HCC
stem cells. For instance, lncTCF7 can alter the expres-
sion of TCF7 by recruiting SWI/SNF to combine with
the TCF7 promoter region, which could activate the
WNT signaling pathways and accelerate self-renewal of
HCC stem cells and the deterioration of HCC [46] (Fig. 2
(Part 3)). LncRNA DILC can inhibit the self-renewal of
HCC stem cells by blocking the HCC autocrine IL-6/
STAT3 signaling pathway [47] (Fig. 2 (Part 4)). Moreover,
LncRNAs can also take part in regulating the self-renewal
and proliferation of HCC stem cells via inhibiting the
combination of microRNA and target genes, playing a role
in secretion in the tumor microenvironment [48, 49]. In
conclusion, the results of several studies have indicated
that LncRNAs play important roles in the malignant
transformation of HCC stem cells, providing a new possi-
bility for HCC clinical treatment.
Prostate cancer
Prostate cancer is the second most frequent cancer in
the world [50]. Androgen receptor plays an important
role in the occurrence and development of prostate can-
cer [51]. In the clinic, androgen blockade therapy is the
standard treatment for prostate cancer, but androgen
blocking resistance often appears after 1–2 years [52, 53].
Presently, research regarding the relationship between
LncRNAs and prostate CSCs is still in the beginning
stages. Scientists have found that LncRNA HOTAIR and
Fig. 2 LncRNAs network in malignant transformation of HCC stem cells. Part 1: LncRNA CUDR impacts the malignant proliferation of liver CSCs
trough different pathways. LncRNA CUDR act as oncogene by CUDR-HULC/CUDR-β-catenin signaling pathway; CUDR inhibits the methylation of
gene promoter LncRNA H19 by combining with Cyclin-D to form the complex CUDR-CyclinD1, which upregulates the expression of LncRNA H19
and finally upregulates the expression of TERT and C-Myc to promote self-renewal and proliferation of HCC stem cells; LncRNA CUDR facilitate the
interaction between SET1A and phosphorylated RB1 (pRB1) to be a complex contributing to the high level of H3K4 trimethylation, which took part in
the malignant transformation of HCC stem cells via altering the length of telomere. Part 2: LncRNA HOTAIR can inhibit histone H3K36 trimethylation by
suppressing SETD2. Then, to enhance the malignant proliferation of HCC stem cells via affecting the repair of aged histone, microsatellite stability, and
cell cycle-related genes. Part 3: LncRNA TCF7 alter the expression of TCF7 by recruiting complex SWI/SNF to combine with TCF7 promoter region,
which could activate WNT signaling pathways and accelerate self-renewal of HCC stem cells. Part 4: LncRNA DILC can inhibit liver CSCs’ self-renewal
through the IL-6/STAT3 signaling pathway
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LncRNA H19, which play important roles in liver CSCs
self-renewal, can also affect the function of prostate CSCs.
Lei Li and other researchers have found that after andro-
gen blockade therapy in prostate cancer, a large number
of mast cells can aggregate in the tumor microenviron-
ment and then increase the number of stem cells and pro-
genitor cells through the downstream androgen receptor
signaling pathway. Mast cells enable the PCR2-LncRNA
HOTAIR complex to bind to the 5′-flanking promoter
region of the androgen receptor gene and thus suppress
androgen receptor transcription, thereby affecting the ex-
pression of MMP9 and increasing CD133+ stem/progeni-
tor cells to promote the invasion of prostate cancer [54]
(Fig. 3). Forming complexes with extraneous molecules
and then binding to the promoter of target gene to pre-
vent its transcription is a common working model of
LncRNAs. In prostate cancer, the inhibition of LncRNA
H19 can repress the expression of classic stem cells re-
lated factors SOX2 and Oct4. At the same time, the inhib-
ition of LncRNA H19 could repress the clone forming
ability of prostate CSCs. This indicates that LncRNA H19
plays an important role in the maintenance of stemness in
prostate CSCs [55]. Until now, studies regarding the func-
tions of LncRNA on prostate CSCs are still limited, but it
is believed that additional important LncRNAs will be
found in prostate CSCs.
Breast cancer
Breast cancer has long been a serious threat to the health
of women around the world [56]. With in-depth studies
on the occurrence and development of breast cancer, re-
searchers have found that breast CSCs appear resistant to
chemotherapy, radiotherapy, and hypoxia. Furthermore,
breast CSCs exhibit high tumorigenicity and invasiveness,
which are crucial to the occurrence, development, metas-
tasis, and recurrence of breast cancer. According to the
reports, LncRNAs can affect the characteristics of breast
CSCs through various pathways, and have a great effect
on breast cancer progression. During the occurrence and
progression of breast cancer, the epithelial mesenchymal
transition (EMT) is closely related to the function of
breast CSCs, and numerous LncRNAs can promote or in-
hibit the metastasis and invasion of breast cancer cells by
inducing or inhibiting EMT [57].
Fig. 3 The roles of LncRNAs in malignant transformation of prostate CSCs. The PCR2-LncRNA HOTAIR complex which promotes by prostate tumor
cells which treated with androgen-deprivation therapy (ADT) recruited mast cells to bind to androgen receptor (AR) gene to promote the invasion of
prostate cancer through MMP9 and CD133+ stem/progenitor cells
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Pádua AC and other researchers reported that LncRNA
HOTAIR played a key role in the occurrence of EMT
in breast cancer cells. They found that treatment with
the cytokine TGF-β1 can upregulate the expression of
HOTAIR and induce the occurrence of EMT. While
siRNA HOTAIR can inhibit the EMT induced by TGF-β1,
it can also inhibit the cloning ability of breast cancer cells
[58]. Moreover, Zhang et al. demonstrated that LncRNA
HOTAIR can indirectly inhibit MIR-7, then depress
SETDB1, and reverse the EMT of breast CSCs by down-
regulating the STAT3 pathway [59]. These studies indicate
that LncRNA HOTAIR is a crucial factor in several EMT-
related signaling pathways in breast cancer. Hou et al.
found that LncRNA ROR is highly expressed in breast
cancer tissues and is upregulated during EMT occurrence
in human mammary epithelial cells. At the same time,
the migration and invasion of breast cancer cells are
enhanced and exert characteristics of primary stem
cells. In contrast, silencing LncRNA ROR can inhibit
the growth and lung metastasis of breast cancer cells
[60]. H Li reported that LncRNA 00617 was highly
expressed in breast cancer tissues and can promote the
invasion and EMT in breast cancer cells by activating
the transcription of SOX2. They showed that LncRNA
00617 exhibited carcinogenic activity in breast cancer
[61]. SOX2 is crucial to the characteristics of CSCs
[62]. Shahryari et al. showed that LncRNA SOX2OT is
one of the main regulatory factors of SOX2 and found that
aberrant expression of LncRNA SOX2OT and SOX2 ap-
peared in numerous solid tumors such as breast and lung
cancers [63]. This suggests that LncRNA SOX2OT may
be related to the characteristics of breast CSCs (Fig. 4).
Additionally, Zhou et al. reported that LncRNA-Hh
can enhance the characteristics of CSCs in Twist-
positive breast cancer through the Hedgehog signaling
pathway [64].
In general, LncRNAs typically affect the characteristics
of breast CSCs by influencing the EMT-related signaling
pathways. These research achievements provide a broader
space for us to study on breast CSCs. During the course
of breast cancer treatment, LncRNAs could be used as
new markers for early diagnosis and prognosis forecast
in the future. In addition, they may also be a new thera-
peutic target and provide new ideas for breast cancer
targeted therapy.
Glioma
Glioma is the most common tumor in the central ner-
vous system, and it exhibits a strong invasive ability. Gli-
oma appears to diffusely infiltrate tissue, and the main
current clinical treatment methods are surgery, radio-
therapy, and chemotherapy, but their effect is limited. In
Fig. 4 The roles of LncRNAs in the malignant transformation of breast CSCs. LncRNA HOTAIR affect the EMT phenomenon of breast
cancer through HoxD10/miRNA-7/SETDB1/STAT3 pathway. At the same time, the secreted TGFβ could affect the expression of LncRNA
HOTAIR. LncRNA 00617 and LncRNA SOX2OT contribute to EMT of breast cancer trough modulate SOX2. LncRNA ROR also could regulate
the EMT of breast cancer
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recent years, studies have indicated that the expression
of various LncRNAs are aberrant in glioma. Some of the
LncRNAs showed increased expression in glioma com-
pared with normal nervous tissues. Galasso et al. found
that LncRNA uc.283-plus was specific to pluripotent
stem cells, and it was highly expressed in glioma cells
[65]. Ellis et al. found that LncRNA CRNDE with obvi-
ous stem cell-related properties is highly expressed in
many kinds of tumor cells, including the glioma cells
[66]. Yao et al. reported that LncRNA XIST was highly
expressed in glioma stem cells, and the results of this
study showed that knockdown of the LncRNA XIST in
glioma cells could lead to miR-152 upregulation, which
resulted in the inhibition of CSCs [67]. Nevertheless,
some of the LncRNAs showed decreased expression in
glioma. Feng S reported that the expression level of
LncRNA-ROR in glioma tissues was significantly lower
than the adjacent tissues. Additionally, LncRNA-ROR si-
lencing could significantly enhance the proliferation of
glioma cells and the spheronization of glioma stem cells.
At the same time, the expression of LncRNA-ROR was
negatively correlated with the expression of stem cell
factor KLF4, which indicated that LncRNA-ROR played
an inhibitory role in the proliferation and self-renewal of
glioma stem cells [68] (Fig. 5). In summary, the aberrant
expression of LncRNAs plays an important role in the
malignant transformation and self-renewal of glioma
stem cells. As research continues, LncRNAs may be-
come new targets for the diagnosis and treatment of
glioma.
Conclusions
Research regarding the effect and mechanism of
LncRNAs on CSCs’ self-renewal and malignant trans-
formation is still in the initial stages. However, the exist-
ing research indicates that the aberrant expression of
LncRNAs plays a key role in the self-renewal and malig-
nant transformation of CSCs and tumor progression. At
the present stage, research regarding the effect of
LncRNAs on CSCs mainly concentrates on HCC, pros-
tate cancer, breast cancer, and glioma, and researchers
have found that the mechanisms of LncRNAs in
Fig. 5 The roles of LncRNAs in the malignant transformation of glioma stem cells. LncRNA uc.283-plus, LncRNA CRNDE, LncRNA-ROR, and LncRNA
XIST impact glioma stem cell functions through different pathways. Knockdown of the LncRNA XIST in glioma cells could lead to miR-152 upregulation,
which resulted in the inhibition of CSCs
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different tumors are not consistent (see Additional file 1),
which include changes in histone modification, the regula-
tion of classic stem cell-related signaling pathways such as
SOX2/KLF4, the induction of EMT, and the inhibition of
miRNA function. These findings indicate that LncRNAs
have strong biological effects on the function and mecha-
nisms of CSCs. Additionally, numerous studies have found
that LncRNA HOTAIR, LncRNA H19, and other classical
LncRNAs could regulate the self-renewal and malignant
transformation of CSCs through different mechanisms in
different tumors. In general, the abnormal differentiation
of CSCs is crucial to metastasis and recurrence in a variety
of tumors, and LncRNAs play important roles in the
abnormal differentiation of CSCs. However, up to now,
the researches on cancer stem cells and LncRNAs have
been focused on the influence of LncRNAs aberrant
expression on cancer stem cells’ malignant transform-
ation, but few studies have explored how LncRNAs
change in the tumor environment. In the future, if we
can clarify the relevant mechanisms, it will provide us
with new ideas. We believe that the multiple func-
tions of LncRNAs suggest that they may become
novel promising targets to eradicate tumor stem cells,
which may provide a new possibility for curative treatments
of numerous cancers.
Additional file
Additional file 1: Summary of LncRNAs related pathways in
Hepatocellular carcinoma, Prostate cancer, Breast cancer, and Glioma.
(XLSX 9 kb)
Abbreviations
CSCs: Cancer stem cells; EMT: Epithelial mesenchymal transition;
HCC: Hepatocellular carcinoma; lincRNAs: Long intergenic ncRNAs;




This work was supported by the National Natural Science Foundation of China
(Nos. 81270607, 81400121, and 81541027). The funding allowed the collection
and analysis of data.
Availability of data and materials
The data and material that support the conclusions of this review have been
included within the article.
Authors’ contributions
XH drafted the manuscript. RX performed the selection of literature. SP, XY,
and WY collected the related references. ZT, MX, YZ, and QY prepared the
figures. YW, WH, LS, and JX revised the language. QZ carried out the design
of the review. All authors contributed to this manuscript. All authors read
and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Author details
1Department of Immunology, School of Basic Medical Science, Wuhan
University, Wuhan 430071, China. 2Hubei University of Technology
Engineering and Technology College, Wuhan 430000, China. 3Department of
Oncology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
4Department of Hematology, Zhongnan Hospital of Wuhan University,
Wuhan 430071, China.
Received: 6 November 2016 Accepted: 23 February 2017
References
1. Harrow J, Frankish A, Gonzalez JM, Tapanari E, Diekhans M, Kokocinski F,
Aken BL, Barrell D, Zadissa A, Searle S, Barnes I, Bignell A, Boychenko V, Hunt
T, Kay M, Mukherjee G, Rajan J, Despacio-Reyes G, Saunders G, Steward C,
Harte R, Lin M, Howald C, Tanzer A, Derrien T, Chrast J, Walters N,
Balasubramanian S, Pei B, Tress M, Rodriguez JM, Ezkurdia I, van Baren J, Brent
M, Haussler D, Kellis M, Valencia A, Reymond A, Gerstein M, Guigó R, Hubbard
TJ. GENCODE: the reference human genome annotation for The ENCODE
Project. Genome Res. 2012;22(9):1760–74.
2. Cheng J, Kapranov P, Drenkow J, Dike S, Brubaker S, Patel S, Long J, Stern D,
Tammana H, Helt G, Sementchenko V, Piccolboni A, Bekiranov S, Bailey DK,
Ganesh M, Ghosh S, Bell I, Gerhard DS, Gingeras TR. Transcriptional maps
of 10 human chromosomes at 5-nucleotide resolution. Science. 2005;
308(5725):1149–54.
3. Bertone P, Stolc V, Royce TE, Rozowsky JS, Urban AE, Zhu X, Rinn JL, Tongprasit
W, Samanta M, Weissman S, Gerstein M, Snyder M. Global identification of
human transcribed sequences with genome tiling arrays. Science. 2004;
306(5705):2242–6.
4. Kapranov P, Cheng J, Dike S, Nix DA, Duttagupta R, Willingham AT, Stadler PF,
Hertel J, Hackermüller J, Hofacker IL, Bell I, Cheung E, Drenkow J, Dumais E,
Patel S, Helt G, Ganesh M, Ghosh S, Piccolboni A, Sementchenko V, Tammana
H, Gingeras TR. RNA maps reveal new RNA classes and a possible function for
pervasive transcription. Science. 2007;316(5830):1484–8.
5. Kloc M, Wilk K, Vargas D, Shirato Y, Bilinski S, Etkin LD. Potential structural
role of non-coding and coding RNAs in the organization of the
cytoskeleton at the vegetal cortex of Xenopus oocytes. Development. 2005;
132(15):3445–57.
6. Deniz E, Erman B. Long noncoding RNA (lincRNA), a new paradigm in
gene expression control. Funct Integr Genomics. 2016. doi:10.1007/s10142-
016-0524-x.
7. Wei S, Wang K. Long noncoding RNAs: pivotal regulators in acute myeloid
leukemia. Exp Hematol Oncol. 2016;5:30.
8. Iyer MK, Niknafs YS, Malik R, Singhal U, Sahu A, Hosono Y, Barrette TR, Prensner
JR, Evans JR, Zhao S, Poliakov A, Cao X, Dhanasekaran SM, Wu YM, Robinson
DR, Beer DG, Feng FY, Iyer HK, Chinnaiyan AM. The landscape of long noncoding
RNAs in the human transcriptome. Nat Genet. 2015;47(3):199–208.
9. Sanchez-Mejias A, Tay Y. Competing endogenous RNA networks: tying the
essential knots for cancer biology and therapeutics. J Hematol Oncol.
2015;8:30.
10. Wei S, Zhao M, Wang X, Li Y, Wang K. PU.1 controls the expression of long
noncoding RNA HOTAIRM1 during granulocytic differentiation. J Hematol
Oncol. 2016;9(1):44.
11. Liu XY, Wang L, Yu B, Zhuang QY, Wang YP. Expression Signatures of Long
Noncoding RNAs in Adolescent Idiopathic Scoliosis. Biomed Res Int. 2015;
doi:10.1155/2015/276049.
12. Zeng C, Yu X, Lai J, Yang L, Chen S, Li Y. Overexpression of the long non-
coding RNA PVT1 is correlated with leukemic cell proliferation in acute
promyelocytic leukemia. J Hematol Oncol. 2015;8(1):126.
13. Huang MD, Chen WM, Qi FZ, Xia R, Sun M, Xu TP, Yin L, Zhang EB, De W,
Shu YQ. Long non-coding RNA ANRIL is upregulated in hepatocellular
carcinoma and regulates cell apoptosis by epigenetic silencing of KLF2.
J Hematol Oncol. 2015;8:50.
14. Dong S, Qu X, Li W, Zhong X, Li P, Yang S, Chen X, Shao M, Zhang L. The
long non-coding RNA, GAS5, enhances gefitinib-induced cell death in
innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells
with wide-type EGFR via downregulation of the IGF-1R expression. J
Hematol Oncol. 2015;8:43.
Huang et al. Journal of Hematology & Oncology  (2017) 10:62 Page 7 of 9
15. Xu TP, Huang MD, Xia R, Liu XX, Sun M, Yin L, Chen WM, Han L, Zhang EB,
Kong R, De W, Shu YQ. Decreased expression of the long non-coding RNA
FENDRR is associated with poor prognosis in gastric cancer and FENDRR
regulates gastric cancer cell metastasis by affecting fibronectin1 expression.
J Hematol Oncol. 2014;7:63.
16. Fan Y, Wang YF, Su HF, Fang N, Zou C, Li WF, Fei ZH. Decreased expression
of the long noncoding RNA LINC00261 indicate poor prognosis in gastric
cancer and suppress gastric cancer metastasis by affecting the epithelial-
mesenchymal transition. J Hematol Oncol. 2016;9(1):57.
17. Wang WT, Ye H, Wei PP, Han BW, He B, Chen ZH, Chen YQ. LncRNAs
H19 and HULC, activated by oxidative stress, promote cell migration
and invasion in cholangiocarcinoma through a ceRNA manner. J
Hematol Oncol. 2016;9(1):117.
18. Harrow J, Frankish A, Gonzalez JM, Tapanari E, Diekhans M, Kokocinski F,
Aken BL, Barrell D, Zadissa A, Searle S, Barnes I, Bignell A, Boychenko V, Hunt
T, Kay M, Mukherjee G, Rajan J, Despacio-Reyes G, Saunders G, Steward C,
Harte R, Lin M, Howald C, Tanzer A, Derrien T, Chrast J, Walters N,
Balasubramanian S, Pei B, Tress M, Rodriguez JM, Ezkurdia I, van Baren J, Brent
M, Haussler D, Kellis M, Valencia A, Reymond A, Gerstein M, Guigó R, Hubbard
TJ. GENCODE: the reference human genome annotation for The ENCODE
Project. Genome Res. 2012;22:1760–74.
19. Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, Huarte M, Zuk O,
Carey BW, Cassady JP, Cabili MN, Jaenisch R, Mikkelsen TS, Jacks T, Hacohen
N, Bernstein BE, Kellis M, Regev A, Rinn JL, Lander ES. Chromatin signature
reveals over a thousand highly conserved large noncoding RNAs in mammals.
Nature. 2009;458(7235):223–7.
20. Tian X, Tian J, Tang X, Ma J, Wang S. Long non-coding RNAs in the regulation
of myeloid cells. J Hematol Oncol. 2016;9(1):99.
21. Zhang C, Peng G. Non-coding RNAs: an emerging player in DNA damage
response. Mutat Res Rev Mutat Res. 2015;763:202–11.
22. Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs.
Mol Cell. 2011;43(6):904–14.
23. Eades G, Zhang YS, Li QL, Xia JX, Yao Y, Zhou Q. Long non-coding RNAs in
stem cells and cancer. World J Clin Oncol. 2014;5(2):134–41.
24. Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts.
Annu Rev Med. 2007;58:267–84.
25. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J,
Weissman IL, Wahl GM. Cancer stem cells—perspectives on current status
and future directions: AACR Workshop on cancer stem cells. Cancer Res.
2006;66(19):9339–44.
26. Visvader JE, Linderman GJ. Cancer stem cells in solid tumors:
accumulating evidence and unresolved questions. Nat Rev Cancer.
2008;8(10):755–68.
27. Liu C, Tang DG. MicroRNA regulation of cancer stem cells. Cancer Res. 2011;
71(18):5950–4.
28. Liu K, Hao M, Ouyang Y, Zheng J, Chen D. CD133+ cancer stem cells promoted
by VEGF accelerate the recurrence of hepatocellular carcinoma. Sci Rep.
2017;7:41499.
29. Wang C, Yan FH, Zhang JJ, Huang H, Cui QS, Dong W, Zhang WW, Zhao Y,
Chen HZ, Zhao TJ. OV6+ cancer stem cells drive esophageal squamous cell
carcinoma progression through ATG7-dependent β-catenin stabilization.
Cancer Lett. 2017. doi:10.1016/j.canlet.2017.01.026.
30. Bekaii-Saab T, El-Rayes B. Identifying and targeting cancer stem cells in the
treatment of gastric cancer. Cancer. 2017. doi:10.1002/cncr.30538.
31. Rasheed ZA, Kowalski J, Smith BD, Matsui W. Concise review: emerging
concepts in clinical targeting of cancer stem cells. Stem Cells.
2011;29(6):883–7.
32. Herreros-Villanueva M, Zhang JS, Koenig A, Abel EV, Smyrk TC, Bamlet WR,
de Narvajas AA, Gomez TS, Simeone DM, Bujanda L, Billadeau DD. SOX2
promotes dedifferentiation and imparts stem cell-like features to pancreatic
cancer cells. Oncogenesis. 2013;2:e61.
33. Kumar SM, Liu S, Lu H, Zhang H, Zhang PJ, Gimotty PA, Guerra M, Guo W,
Xu X. Acquired cancer stem cell phenotypes through Oct4-mediated
dedifferentiation. Oncogene. 2012;31(47):4898–911.
34. Yu F, Li J, Chen H, Fu J, Ray S, Huang S, Zheng H, Ai W. Kruppel-like factor 4
[KLF4] is required for maintenance of breast cancer stem cells and for cell
migration and invasion. Oncogene. 2011;30(18):2161–72.
35. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, Diehn M, Liu H,
Panula SP, Chiao E, Dirbas FM, Somlo G, Pera RA, Lao K, Clarke MF.
Downregulation of miRNA-200c links breast cancer stem cells with normal
stem cells. Cell. 2009;138(3):592–603.
36. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, Huang Y, Hu X, Su F, Lieberman J,
Song E. let-7 regulates self renewal and tumorigenicity of breast cancer cells.
Cell. 2007;131(6):1109–23.
37. Li Q, Yao Y, Eades G, Liu Z, Zhang Y, Zhou Q. Downregulation of miR-140
promotes cancer stem cell formation in basal-like early stage breast cancer.
Oncogene. 2014;33(20):2589–600.
38. Laursen L. A preventable cancer. Nature. 2014;516(7529):S2–3.
39. Maluccio M, Covey A. Recent progress in understanding, diagnosing, and
treating hepatocellular carcinoma. CA Cancer J Clin. 2012;62(6):394–9.
40. He C, Xu J, Zhang J, Xie D, Ye H, Xiao Z, Cai M, Xu K, Zeng Y, Li H, Wang J.
High expression of trimethylated histone H3 lysine 4 is associated with
poor prognosis in hepatocellular carcinoma. Hum Pathol. 2012;43(9):
1425–35.
41. Cai MY, Hou JH, Rao HL, Luo RZ, Li M, Pei XQ, Lin MC, Guan XY, Kung HF,
Zeng YX, Xie D. High expression of H3K27me3 in human hepatocellular
carcinomas correlates closely with vascular invasion and predicts worse
prognosis in patients. Mol Med. 2011;17(1-2):12–20.
42. Li T, Zheng Q, An J, Wu M, Li H, Gui X, Pu H, Lu D. SET1A cooperates with
CUDR to promote liver cancer growth and hepatocyte-like stem cell
malignant transformation epigenetically. MolTher. 2016;24(2):261–75.
43. Gui X, Li H, Li T, Pu H, Lu D. Long noncoding RNA CUDR regulates HULC
and β-Catenin to govern human liver stem cell malignant differentiation.
MolTher. 2015;23(12):1843–53.
44. Pu H, Zheng Q, Li H, Wu M, An J, Gui X, Li T, Lu D. CUDR promotes liver
cancer stem cell growth through upregulating TERT and C-Myc. Oncotarget.
2015;6(38):40775–98.
45. Li H, An J, Wu M, Zheng Q, Gui X, Li T, Pu H, Lu D. LncRNA HOTAIR promotes
human liver cancer stem cell malignant growth through downregulation of
SETD2. Oncotarget. 2015;6(29):27847–64.
46. Wang Y, He L, Ying D, Zhu P, Huang G, Luo J, Yan X, Ye B, Li C, Xia P, Zhang G,
Tian Y, Chen R, Fan Z. The long noncoding RNA lncTCF7 promotes self-renewal
of human liver cancer stem cells through activation of Wnt signaling. Cell Stem
Cell. 2015;16(4):413–25.
47. Wang X, Sun W, Shen W, Xia M, Chen C, Xiang D, Ning B, Cui X, Li H, Li X, Ding J,
Wang H. Long non-coding RNA DILC represses self-renewal of liver cancer stem
cells via inhibiting autocrine IL-6/STAT3 axis. J Hepatol. 2016;64(6):1283–94.
48. Yuan SX, Wang J, Yang F, Tao QF, Zhang J, Wang LL, Yang Y, Liu H, Wang
ZG, Xu QG, Fan J, Liu L, Sun SH, Zhou WP. Long noncoding RNA DANCR
increases stemness features of hepatocellular carcinoma by derepression of
CTNNB1. Hepatology. 2016;63(2):499–511.
49. Conigliaro A, Costa V, Lo Dico A, Saieva L, Buccheri S, Dieli F, Manno M,
Raccosta S, Mancone C, Tripodi M, De Leo G, Alessandro R. CD90+ liver
cancer cells modulate endothelial cell phenotype through the release of
exosomes containing H19 LncRNA. Mol Cancer. 2015;14:155.
50. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer
statistics. CA Cancer J Clin. 2011;61(2):69–90.
51. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev.
2004;25(2):276–308.
52. Niu Y, Chang TM, Yeh S, Ma WL, Wang YZ, Chang C. Differential androgen
receptor signals in different cells explain why androgen-deprivation therapy
of prostate cancer fails. Oncogene. 2010;29(25):3593–604.
53. Chang C, Lee SO, Yeh S, Chang TM. Androgen receptor [AR] differential
roles in hormone-related tumors including prostate, bladder, kidney, lung,
breast and liver. Oncogene. 2014;33(25):3225–34.
54. Li L, Dang Q, Xie H, Yang Z, He D, Liang L, Song W, Yeh S, Chang C.
Infiltrating mast cells enhance prostate cancer invasion via altering LncRNA-
HOTAIR/PRC2-androgen receptor [AR]-MMP9 signals and increased stem/
progenitor cell population. Oncotarget. 2015;6(16):14179–90.
55. Bauderlique-Le Roy H, Vennin C, Brocqueville G, Spruyt N, Adriaenssens E,
Bourette RP. Enrichment of human stem-like prostate cells with s-SHIP
promoter activity uncovers a role in stemness for the long noncoding RNA
H19. Stem Cells Dev. 2015;24(10):1252–62.
56. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;
66(1):7–30.
57. Ye X, Tam WL, Shibue T, Kaygusuz Y, Reinhardt F, Ng Eaton E, Weinberg RA.
Distinct EMT programs control normal mammary stem cells and tumour-
initiating cells. Nature. 2015;525(7568):256–60.
58. Pádua Alves C, Fonseca AS, Muys BR, de Barros E Lima Bueno R, Bürger MC,
de Souza JE, Valente V, Zago MA, Silva Jr WA. Brief report: the lincRNA
Hotair is required for epithelial-to-mesenchymal transition and stemness
maintenance of cancer cell lines. Stem Cells. 2013;31(12):2827–32.
Huang et al. Journal of Hematology & Oncology  (2017) 10:62 Page 8 of 9
59. Zhang H, Cai K, Wang J, Wang X, Cheng K, Shi F, Jiang L, Zhang Y, Dou J.
MiR-7, inhibited indirectly by lincRNA HOTAIR, directly inhibits SETDB1 and
reverses the EMT of breast cancer stem cells by downregulating the STAT3
pathway. Stem Cells. 2014;32(11):2858–68.
60. Hou P, Zhao Y, Li Z, Yao R, Ma M, Gao Y, Zhao L, Zhang Y, Huang B, Lu J.
LincRNA-ROR induces epithelial-to-mesenchymal transition and contributes
to breast cancer tumorigenesis and metastasis. Cell Death Dis. 2014;5:e1287.
61. Li H, Zhu L, Xu L, Qin K, Liu C, Yu Y, Su D, Wu K, Sheng Y. Long noncoding
RNA linc00617 exhibits oncogenic activity in breast cancer. MolCarcinog.
2015. doi:10.1002/mc.22338.
62. Zhou C, Yang X, Sun Y, Yu H, Zhang Y, Jin Y. Comprehensive profiling
reveals mechanisms of SOX2-mediated cell fate specification in human
ESCs and NPCs. Cell Res. 2016;26(2):171–89.
63. Shahryari A, Jazi MS, Samaei NM, Mowla SJ. Long non-coding RNA SOX2OT:
expression signature, splicing patterns, and emerging roles in pluripotency
and tumorigenesis. Front Genet. 2015;6:196.
64. Zhou M, Hou Y, Yang G, Zhang H, Tu G, Du YE, Wen S, Xu L, Tang X, Tang
S, Yang L, Cui X, Liu M. LncRNA-Hh strengthen cancer stem cells generation
in Twist-positive breast cancer via activation of hedgehog signaling pathway.
Stem Cells. 2016;34(1):55–66.
65. Galasso M, Dama P, Previati M, Sandhu S, Palatini J, Coppola V, Warner S,
Sana ME, Zanella R, Abujarour R, Desponts C, Teitell MA, Garzon R, Calin G,
Croce CM, Volinia S. A large scale expression study associates uc.283-plus
LncRNA with pluripotent stem cells and human glioma. Genome Med.
2014;6(10):76.
66. Ellis BC, Molloy PL, Graham LD. CRNDE: a long non-coding RNA involved in
cancer, neurobiology, and development. Front Genet. 2012;3:270.
67. Yao Y, Ma J, Xue Y, Wang P, Li Z, Liu J, Chen L, Xi Z, Teng H, Wang Z, Li Z,
Liu Y. Knockdown of long non-coding RNA XIST exerts tumor-suppressive
functions in human glioblastoma stem cells by up-regulating miR-152.
Cancer Lett. 2015;359(1):75–86.
68. Feng S, Yao J, Chen Y, Geng P, Zhang H, Ma X, Zhao J, Yu X. Expression and
functional role of reprogramming-related long noncoding RNA (lincRNA-
ROR) in glioma. J Mol Neurosci. 2015;56(3):623–30.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Huang et al. Journal of Hematology & Oncology  (2017) 10:62 Page 9 of 9
